Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 9/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4627473 | 0.77 | XDH (0.51) | XDHALDH1A1SMN1; SMN2LMNAJAK2 | |
| SCHEMBL8241597 | 0.76 | XDH (0.44) | XDHALDH1A1SMN1; SMN2LMNAJAK2 | |
| SCHEMBL3700367 | 0.74 | XDH (0.49) | XDHALDH1A1SMN1; SMN2LMNAJAK2 | |
| Oxypurinol SCHEMBL8257647 | 0.73 | XDH (0.48) | XDHALDH1A1SMN1; SMN2LMNAJAK2 | |
| SCHEMBL18701487 | 0.72 | ALDH1A1 (0.56) | XDHALDH1A1SMN1; SMN2LMNAHTT | |
| SCHEMBL16212717 | 0.72 | TYMP (0.42) | L3MBTL1ALDH1A1SMN1; SMN2JAK2JAK1 | |
| SCHEMBL24351056 | 0.72 | XDH (0.44) | XDHALDH1A1LMNAJAK2JAK1 | |
| SCHEMBL10779485 | 0.67 | ALDH1A1 (0.44) | L3MBTL1ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL17731840 | 0.67 | L3MBTL1 (0.38) | L3MBTL1 | |
| SCHEMBL1847814 | 0.64 | CYP1A2 (0.41) | XDHLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220235032-A1 | BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2022-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235032-A1 | BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | RIPK1, RIPK4, RIPK3 | XDH 2248/4885L3MBTL1 4089/4885ALDH1A1 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.